Amitriptyline and Paroxetine Treatment of Major Depression

Last updated: January 30, 2024
Sponsor: Central Institute of Mental Health, Mannheim
Overall Status: Completed

Phase

3

Condition

Depression

Depression (Major/severe)

Depression (Treatment-resistant)

Treatment

paroxetine

amitriptyline

Clinical Study ID

NCT01049347
AmiPar
DFG De 660/1-1
  • Ages > 18
  • All Genders

Study Summary

Activation of the hypothalamus-pituitary-adrenal system is monitored using saliva cortisol sampling during the antidepressant treatment with amitriptyline and paroxetine in moderately to severely depressed patients. Additionally, serum and plasma are sampled during the 5-week study period in order to study endocrine and metabolic parameters.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • age: above 18
  • depression according DSM-IV

Exclusion

Exclusion Criteria:

  • bipolar disorder
  • substance dependency

Study Design

Total Participants: 127
Treatment Group(s): 2
Primary Treatment: paroxetine
Phase: 3
Study Start date:
October 01, 1997
Estimated Completion Date:
May 31, 2000

Connect with a study center

  • Central Institute of Mental Health

    Mannheim, 68159
    Germany

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.